Almonertinib
- Generic Name
- Almonertinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H35N7O2
- CAS Number
- 1899921-05-1
- Unique Ingredient Identifier
- T4RS462G19
- Background
Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
- Indication
1.用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。
2.用于表皮生长因子受体（EGFR）敏感突变阳性局部晚期或转移性非小细胞肺癌（NSCLC）患者一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 60
- Registration Number
- NCT06463171
- Locations
- 🇨🇳
Zhongshan hospital, Shanghai, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, China
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06300424
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Qianfoshan Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT06043973
- Locations
- 🇨🇳
Degan Lu, Jinan, Shandong, China
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Laibin People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05994339
Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Guangzhou Institute of Respiratory Disease
- Target Recruit Count
- 20
- Registration Number
- NCT05826483
- Locations
- 🇨🇳
Zhou Chengzhi, Guangzhou, Guangdong, China
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Shanghai Cancer Hospital, China
- Target Recruit Count
- 300
- Registration Number
- NCT05800223
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 232
- Registration Number
- NCT05768490
- Locations
- 🇨🇳
Sun-Yat-Sen university, Guangdong, Guangzhou, China
Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT05662813
- Locations
- 🇨🇳
West China Hospital，Sichuan University, Chendu, Sichuan, China
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT05503888
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
- Conditions
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT04951648
- Locations
- 🇨🇳
Sun yat-sen Univerisity Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.